Download Files:
Saroglitazar
$188 – $2,760
Products Details
Product Description
– Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
Web ID
– HY-19937
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Metabolism-sugar/lipid metabolism
Molecular Formula
– C25H29NO4S
Citations
– Cell Biol Toxicol. 2020 Jul 1. |Patent. US20190388398A1.|BMC Complement Med Ther. 2021 Apr 10;21(1):118.|Patent. US20210275504A1.
References
– [1]Jain MR, et al. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e00136.
CAS Number
– 495399-09-2
Molecular Weight
– 439.57
Compound Purity
– 99.10
SMILES
– OC([C@@H](OCC)CC1=CC=C(OCCN2C(C)=CC=C2C3=CC=C(SC)C=C3)C=C1)=O
Clinical Information
– Phase 4
Research Area
– Metabolic Disease
Solubility
– DMSO : ≥ 25 mg/mL
Target
– PPAR
Isoform
– PPARα;PPARγ
Pathway
– Cell Cycle/DNA Damage;Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
